Clinical and Molecular Hepatology10.3350/cmh.2014.20.3.2742014203274Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis BJeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon,
Journal of Hepatology10.1016/s0168-8278(05)81916-6200542182504 Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B,
Journal of Viral Hepatitis10.1111/j.1365-2893.2008.01047.x20081512922-924Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudineM. Viganò, P. Lampertico, F. Facchetti, G. Lunghi, M. Colombo
Liver International10.1111/j.1478-3231.2008.01685.x2008286814-820Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosisWon Hyeok Choe, So Young Kwon, Byung Kook Kim, Soon Young Ko, Jong Eun Yeon, Kwan Soo Byun, Gyun-Hwan Kim, Chang Hong Lee
Journal of Gastroenterology and Hepatology10.1111/j.1440-1746.2010.06381.x20102581374-1380Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapyHong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
The Korean Journal of Hepatology10.3350/kjhep.2008.14.2.2352008142235Adefovir plus lamivudine combination therapy in lamivudine-resistant chronic hepatitis BSo Young Kwon,
Journal of Hepatology10.1016/s0168-8278(05)81913-0200542181501 Adefovir dipivoxil alone or in combination with lamivudine in HBeAg negative patients with lamivudine resistant chronic hepatitis B: A prospective, randomized study,
Journal of Hepatology10.1016/s0168-8278(05)81513-220054244101 High levels of HBsAg clearance after adefovir dipivoxil treatment in patients with chronic hepatitis B lamivudine-resistant post liver transplant,
Liver Transplantation10.1002/lt.236002013193268-274Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidatesEdward J. Gane, Scott Patterson, Simone I. Strasser, Geoffrey W. McCaughan, Peter W. Angus,
Journal of Viral Hepatitis10.1111/j.1365-2893.2010.01301.x2011183206-215Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation patternJ. Inoue, Y. Ueno, Y. Wakui, H. Niitsuma, K. Fukushima, Y. Yamagiwa, M. Shiina, Y. Kondo, E. Kakazu, K. Tamai, N. Obara, T. Iwasaki, T. Shimosegawa